Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| + | ''Not FDA approved, but is approved for use in China.'' | ||
| + | |||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tucidinostat NCI Drug Dictionary]: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tucidinostat NCI Drug Dictionary]: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. | ||
| Line 5: | Line 7: | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| − | |||
| − | |||
| − | |||
==Also known as== | ==Also known as== | ||
Revision as of 13:04, 8 May 2021
Not FDA approved, but is approved for use in China.
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells.
Diseases for which it is used
Also known as
- Code names: CS055, HBI-8000
- Generic name: tucidinostat
- Brand name: Epidaza